单株抗体合作与授权协议：2019-2025

Monoclonal Antibody Collaboration and Licensing Deals 2019-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告全面深入分析了全球领先的生物製药公司签署的单株抗体协议，并提供前所未有的资讯取得管道。

本报告详细阐述并分析了公司签署单株抗体协议的原因和方法。这些协议通常包含多个组成部分，从合作研发开始，最终实现成果的商业化。

本报告涵盖合作研发、研究和授权协议。

本报告包含自2019年以来公布的670项单株抗体交易的完整清单，其中包括可用的财务条款以及指向相关方披露的实际单株抗体合作交易线上记录的连结。此外，在条件允许的情况下，记录中还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

主要优势：

了解 2019 年及以后的合约趋势
查看单株抗体领域的合作与授权协议
基准分析：确定交易市场价值
财务条款：预付款、里程碑付款、特许权使用费
依公司名称（A-Z）、合约类型和治疗领域分类的合约目录
以价值排名的主要交易
最活跃的交易撮合者
识别每份合约的资产描述和条款
存取合约文件：深入了解合约结构
尽职调查：评估拟议合约条款是否适合您的合作伙伴
节省数百小时的研究时间

分析合约内容有助于进行以下方面的尽职调查：

合约授予或选择哪些具体权利？
合约实际上赋予合作伙伴哪些权利？
授予了哪些独家经营权？
合约的付款结构是怎样的？
销售和付款将如何审计？
合约期限是多久？
合约的关键条款是如何定义的？
智慧财产权（IPR）将如何处理，所有权归谁？
谁负责商业化？
谁负责开发、供应和生产？
如何管理保密和资讯揭露？
如何解决争议？
在什么情况下可以终止合约？
如果所有权发生变更，会发生什么事？
双方约定的转授权和分包条款是什么？
公司通常会包含哪些标准条款？
根据交易对手和合约类型，有哪些标准条款会有所不同？
根据合约法，公司要求适用哪个司法管辖区（法院）的法律？

This report contains a comprehensive listing of 670 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in monoclonal antibody dealmaking in the biopharma industry
Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading monoclonal antibody deals by value
Most active monoclonal antibody licensing dealmakers
Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
- 2.7.1 Monoclonal antibody deals headline values
- 2.7.2 Monoclonal antibody deal upfront payments
- 2.7.3 Monoclonal antibody deal milestone payments
- 2.7.4 Monoclonal antibody royalty rates